The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research licensees and /or co-development partners under a Cooperative Research and Development Agreement (CRADA) to advance preclinical and clinical development of methods to treat Alzheimer Disease using Carboxypeptidase E (CPE).
Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.
The National Institute on Aging (NIA) seeks research licensees and/or co-development partners under a Cooperative Research and Development Agreement (CRADA) to advance preclinical and clinical development of repurposed compounds to treat Alzheimer’s disease.
Researchers at the NICHD seek licensing and/or co-development research collaborations for an MRI method that is based on the measurement and acquisition of multiple pulsed field gradient (m-PFG) rather than the previously used single pulsed field gradient (s-PFG) MRI sequences.
The technology is a series of modafinil analogues that bind with moderate to high affinity to the dopamine (DA) transporter (DAT). Some compounds also have affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. The compounds retain the desired dopamine transporter affinity with greater metabolic stability over previously described unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment. Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations for further development and commercialization of the compounds.
Researchers at the NICHD developed a method for non-invasively determining the distribution of pore lengths and radii within a matrix thereby characterizing cognitive defects observed in patients with Traumatic Brain Injury (TBI). The NICHD seeks licensing and/or co-development research collaborations to bring this invention to the public.
A library of novel compounds that selectively bind the dopamine D3 receptor have been designed and characterized extensively. In vivo rodent studies indicate selected lead molecules may be useful to treat drug addiction/dependence.
Hibernation in mammals is a seasonal state of metabolic suppression and dormancy characterized by a decrease in body temperature to survive extreme environmental stresses. A new Induced Pluripotent Stem Cell (iPSC) line has been established from the neural precursor cells of wild type thirteen-lined ground squirrel (Spermophilus tridecemlineatus), a small mammalian hibernator with unique metabolic adaptations for coping with cold and restricted food supply. This ground squirrel iPSC line can be differentiated into many different cell types for hibernation studies, disease modeling, and drug screening for neuronal injuries or other diseases.
The Section on Translational Neuroscience of NICHD seeks parties interested in licensing and/or collaborative research to co-develop this therapeutic management of Menkes Disease and related copper transport disorders.
Scientists at the National Institute on Drug Abuse (NIDA) have developed novel dopamine D3 receptor (D3R) agonists with high affinity and selectivity. Two lead compounds, 53 and eutomer 53a, have demonstrated significantly higher D3R binding selectivity than reference compounds. Moreover, 53 and 53a showed metabolic stability in liver microsomes, which is favorable for the future use of these compounds as therapeutic agents for diseases related to dopamine system dysregulation such as Parkinson’s Disease and Restless Legs Syndrome. Researchers at NIDA seek licensing and/or co-development research collaborations for the use of these D3R agonists as molecular tools for the study of D3R physiology and as potential therapeutics to treat neurological and neuropsychiatric disorders.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for size- dependent macro molecular drug delivery platform for neurological disorders, brain cancers, and infectious diseases.
Investigators at the National Center for Complimentary and Integrative Health (NCCIH) and the University of Tennessee Health and Science Center have shown that administration of margaric acid can ameliorate pain induced by a variety of noxious stimuli in mice. In vitro and ex vivo studies in human and murine neural cells indicate that the mechanism of action of margaric acid is mediated by PIEZO2 (Piezo-type mechanosensitive ion channel component 2) function. NCCIH seeks research co-development partners and/or licensees for methods of using the fatty acid, margaric acid to treat pain.
The Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) seeks research and co-development partners or licensees for an invention that discloses the diagnosis of pathologies in tissue related to changes in cell size, cellularity, cell infiltration, and other abnormalities detected by bulk water diffusion changes.
The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.